Your Guide to the Breast Cancer Pathology Report

Total Page:16

File Type:pdf, Size:1020Kb

Load more

Your Guide to the Breast Cancer Pathology Report Developed for you by Breastcancer.org is a nonprofit organization dedicated to providing education and information on breast health and breast cancer. The pathology report is used by your doctor to determine which treatments are right for you. Your Guide to the Breast Cancer Pathology Report A report is written each time tissue is removed from the body to check for cancer. These are called pathology reports. Each report has the results of the studies done on the removed tissue. The information in these reports will help you and your doctors decide on the best treatment for you. Reading your pathology report can be scary and confusing. Different labs may use different words to describe the same thing. On page 34, you’ll find an easy-to-understand word list. We hope we can help you make sense of this information so you can get the best care possible. TABLE OF CONTENTS Wait for the Whole Picture • Waiting for test results ............................2 • How much cancer is in each lymph node? ..........................................17 • Get all the information you need .............3 • Do the cancer cells have • Parts of your pathology report .................4 hormone receptors? ..............................18 Reading Your Pathology Report • Does the cancer have genes that • The pathology report answers affect how the cancer might questions about a breast abnormality ......6 be treated? .............................................20 • Genetic testing that is not a part of • Is the breast abnormality a cancer? ........6 your pathology report .............................25 • Is the breast cancer invasive? ..................7 • What stage is the breast cancer? .........28 • How different are the cancer cells — Stage 0 ..............................................28 from normal cells?...................................9 — Stage I ...............................................29 • How fast are the cancer cells growing? ................................................10 — Stage II ..............................................30 • How big is the cancer? .........................12 — Stage III ............................................31 • Has the whole cancer — Stage IV ............................................33 been removed? ......................................13 Word List .................................................34 • Are there cancer cells in your lymph channels or blood vessels? ...................15 Key Questions .........................................44 • Are there cancer cells in your Pathology Report Checklist ...................45 lymph nodes? ........................................16 • How many lymph nodes Notes .......................................................46 are involved?..........................................17 WAIT FOR THE WHOLE PICTURE Waiting for test results Get all the information you need When you have all of the test results, When you have all the test information you and your doctor can make the you need, you and your doctor can right decisions for you. The analysis of make a final decision about your the removed tissue can lead to several treatment. Don’t focus too much on any different reports. Some tests take longer one piece of information by itself. Try to than others. Not all tests are done by look at the whole picture as you think the same lab. Most information comes about your options. within 1 to 2 weeks after surgery, and Different labs and hospitals may you will usually have all the results use different words to describe the within a few weeks. Your doctor can let same thing. If there are words in your you know when the results come in. If pathology report that are not explained you don’t hear from your doctor, call in this booklet, don’t be afraid to ask the office. your doctor what they mean. For more information, go to: www.breastcancer.org EXPERT TIP: Marisa Weiss, M.D., breast cancer doctor “The information in your pathology report three lab reports from one surgery. Together, often comes in bits and pieces. Just after the lab reports make up your pathology surgery, the cancer cells are first looked at report. Try to keep all your reports in one under the microscope. Results from additional place, so that when you go for your treatment studies that require special techniques may evaluations, the doctors will have all the take longer. So you may have one, two, or information they need.” 2 3 WAIT FOR THE WHOLE PICTURE (continued) Parts of your pathology report Personal information. Make sure it’s Gross description. This section describes your correct name and date of operation the pieces of tissue removed. It talks at the top of the report. about the size, weight, and color of each piece. Specimen. This section describes where the tissue samples came from. Tissue Microscopic description. This section samples could be taken from the breast, describes the way the cancer cells look from the lymph nodes under your arm under the microscope, their relationship (axilla), or both. to the normal surrounding tissue, and the size of the cancer. Clinical history. This is a short description of you and how the breast Special tests or markers. This section abnormality was found. It also describes reports the results of tests for proteins, the kind of surgery that was done. genes, and cell growth rate. Clinical diagnosis. This is the diagnosis Summary or final diagnosis. This section the doctors were expecting before your is the short description of all the important tissue sample was tested. findings in all of the tissue examined. For more information, go to: www.breastcancer.org 4 5 READING YOUR PATHOLOGY REPORT The pathology report answers questions may grow into the normal tissue around about a breast abnormality them. Cancer cells may also spread beyond the breast. Breast tissue can develop abnormalities that are sometimes cancerous. Usually The abnormal lump or spot may be found breast cancer begins either in the cells using mammography or other testing of the lobules, which are milk-producing methods. A procedure called a biopsy glands, or the ducts, the passages that removes a piece of tissue from the lump or drain milk from the lobules to the nipple. spot to find out if cancer cells are present. Breast cancers have many characteristics The pathology report will tell you what that help determine the best treatment. kinds of cells are present. Is the breast abnormality a cancer? Is the breast cancer invasive? A lump or spot in the breast can be made If breast cancer is found, it’s important of normal cells or cancer cells. There can to know whether the cancer has spread also be cells that fall somewhere between outside the milk ducts or lobules of the normal and cancerous (“atypical” cells). breast where it started. Cancer cells are cells that grow in an Non-invasive cancers stay within the milk uncontrolled way. They may stay in the ducts or milk lobules in the breast. They place where they started to grow, or they do not grow into or invade normal tissues This is what the inside within or beyond the breast. Non-invasive of a breast looks like. cancers are sometimes called in situ or pre-cancers. The real size of a normal If the cancer has grown into normal duct or lobule rib cage tissues, it is called invasive. Most breast fat is smaller chest wall than this cancers are invasive. Sometimes cancer . cells spread to other parts of the body through the blood or lymph system. When muscle lobule cancer cells spread to other parts of the duct body, it is called metastatic breast cancer. In some cases, a breast cancer may be both invasive and non-invasive. nipple non- This is what normal cells invasive invasive inside a milk duct look cells cells like under a microscope. 6 7 READING YOUR PATHOLOGY REPORT (continued) You may see these descriptions of the How different are the cancer cells type of cancer cells in your report: from normal cells? DCIS (Ductal Carcinoma In Situ). This is a cancer that is non-invasive. It stays Grade is how different the cancer cells inside the milk ducts. are from normal cells. Experts compare the appearance of the cancer cells to NOTE: There are subtypes of DCIS. You’ll normal breast cells. Based on these find their names in the word list that begins comparisons, they give a grade to the on page 34 of this booklet. cancer. Grade is different from stage LCIS (Lobular Carcinoma In Situ). This (see page 28 for information about is a tumor that is an overgrowth of cells stage). that stay inside the milk-making part There are three cancer grades: of the breast (called lobules). LCIS is not a true cancer. It’s a warning sign Grade 1 (low grade or well of an increased risk for developing an differentiated). Grade 1 cancer cells look invasive cancer in the future in either a little bit different from normal cells. breast. They are usually slow-growing. IDC (Invasive Ductal Carcinoma). This is Grade 2 (intermediate/moderate grade a cancer that begins in the milk duct but or moderately differentiated). Grade 2 has grown into the surrounding normal cancer cells do not look like normal cells. tissue inside the breast. This is the most They are growing a little faster than common kind of breast cancer. normal. ILC (Invasive Lobular Carcinoma). This Grade 3 (high grade or poorly is a cancer that starts inside the milk- differentiated). Grade 3 cancer cells look making glands (called lobules), but very different from normal cells. They are grows into the surrounding normal fast-growing. tissue inside the breast. NOTE: There are other, less common types of invasive breast cancer. You’ll find their names in the word list beginning on page 34 of this booklet. For more information, go to: www.breastcancer.org MY REPORT SAYS: The type of cancer I have is ______________ The cancer is: (check one) _______________________________________ . j Grade 1 j Grade 2 j Grade 3 8 9 READING YOUR PATHOLOGY REPORT (continued) How fast are the cancer cells In breast cancer, a result of less than growing? 10% is considered low, 10-20% is intermediate/borderline, and more Your pathology report may include than 20% is considered high.
Recommended publications
  • Signs and Symptoms of Metastatic Breast Cancer (Mbc)

    Signs and Symptoms of Metastatic Breast Cancer (Mbc)

    After Early Breast Cancer – SIGNS AND SYMPTOMS OF METASTATIC BREAST CANCER (MBC) Metastatic Breast Cancer After treatment for early or locally advanced breast cancer (stages I, II and III), it’s possible for breast cancer to return (recur) and spread to other parts of the body (metastasize). This is called metastatic breast cancer (MBC). The most common sites for breast cancer to spread are the brain, lung, liver and/or bones. It’s the most advanced stage of breast cancer, also known as stage IV breast cancer. The risk of MBC varies from person to person. Most people will not develop MBC, but it’s important to be aware of the signs and symptoms. Signs and Symptoms This picture below shows the most common signs and symptoms of MBC. If you’ve been treated for breast cancer and any of these signs or symptoms persist for 2 weeks or longer – tell your doctor. They may be related to other health conditions or side effects from treatment, but could be signs of recurrence. Brain m Attention or memory problems m Blurred vision, dizziness or headaches m Seizures m Loss of balance m Constant nausea or vomiting m Confusion or personality changes Lung m Hoarseness or constant dry cough m Shortness of breath or difficulty breathing Liver m Itchy skin or rash m Yellowing of skin or whites of eyes (jaundice) m Pain or swelling in belly m Digestive problems such as change in bowel habits or loss of appetite Bone m Bone, back, neck or joint pain m Bone fractures m Swelling Other signs and symptoms: m Fatigue m Weight loss m Difficulty urinating m Increased lymph node size under arm or other places This information is important, but remember most people with these signs and symptoms will not have MBC.
  • Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary

    Primary Screening for Breast Cancer with Conventional Mammography: Clinical Summary

    Primary Screening for Breast Cancer With Conventional Mammography: Clinical Summary Population Women aged 40 to 49 y Women aged 50 to 74 y Women aged ≥75 y The decision to start screening should be No recommendation. Recommendation Screen every 2 years. an individual one. Grade: I statement Grade: B Grade: C (insufficient evidence) These recommendations apply to asymptomatic women aged ≥40 y who do not have preexisting breast cancer or a previously diagnosed high-risk breast lesion and who are not at high risk for breast cancer because of a known underlying genetic mutation Risk Assessment (such as a BRCA1 or BRCA2 gene mutation or other familial breast cancer syndrome) or a history of chest radiation at a young age. Increasing age is the most important risk factor for most women. Conventional digital mammography has essentially replaced film mammography as the primary method for breast cancer screening Screening Tests in the United States. Conventional digital screening mammography has about the same diagnostic accuracy as film overall, although digital screening seems to have comparatively higher sensitivity but the same or lower specificity in women age <50 y. For women who are at average risk for breast cancer, most of the benefit of mammography results from biennial screening during Starting and ages 50 to 74 y. While screening mammography in women aged 40 to 49 y may reduce the risk for breast cancer death, the Stopping Ages number of deaths averted is smaller than that in older women and the number of false-positive results and unnecessary biopsies is larger. The balance of benefits and harms is likely to improve as women move from their early to late 40s.
  • Mitogen-Activated Protein Kinase Signalling in Experimental Models

    Mitogen-Activated Protein Kinase Signalling in Experimental Models

    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by PubMed Central Available online http://breast-cancer-research.com/content/11/5/209 Review Key signalling nodes in mammary gland development and cancer Mitogen-activated protein kinase signalling in experimental models of breast cancer progression and in mammary gland development Jacqueline Whyte1, Orla Bergin2, Alessandro Bianchi2, Sara McNally2 and Finian Martin2 1Current address: Physiology and Medical Physics, Royal College of Surgeons in Ireland, St Stephens Green, Dublin 2, Ireland 2UCD Conway Institute and School of Biomolecular and Biomedical Science University College Dublin, Belfield, Dublin 4, Ireland Corresponding author: Finian Martin, [email protected] Published: 29 September 2009 Breast Cancer Research 2009, 11:209 (doi:10.1186/bcr2361) This article is online at http://breast-cancer-research.com/content/11/5/209 © 2009 BioMed Central Ltd Abstract pathway, in particular, has been implicated as being Seven classes of mitogen-activated protein kinase (MAPK) important [3]. Signalling through each pathway involves intracellular signalling cascades exist, four of which are implicated sequential activation of a MAPK kinase kinase (MAPKKK), a in breast disease and function in mammary epithelial cells. These MAPK kinase (MAPKK) and the MAPK. Considering the are the extracellular regulated kinase (ERK)1/2 pathway, the ERK5 ERK1/2 pathway, the primary input activator is activated Ras, pathway, the p38 pathway and the c-Jun N-terminal kinase (JNK) a small GTPase. It activates Raf1 (MAPKKK), which then pathway. In some forms of human breast cancer and in many phosphorylates and activates MEK1/2 (MAPKK), which finally experimental models of breast cancer progression, signalling through the ERK1/2 pathway, in particular, has been implicated as activates ERK1/2 [1].
  • Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology by Thea Liza Batan About the Author

    Study Guide Medical Terminology By Thea Liza Batan About the Author Thea Liza Batan earned a Master of Science in Nursing Administration in 2007 from Xavier University in Cincinnati, Ohio. She has worked as a staff nurse, nurse instructor, and level department head. She currently works as a simulation coordinator and a free- lance writer specializing in nursing and healthcare. All terms mentioned in this text that are known to be trademarks or service marks have been appropriately capitalized. Use of a term in this text shouldn’t be regarded as affecting the validity of any trademark or service mark. Copyright © 2017 by Penn Foster, Inc. All rights reserved. No part of the material protected by this copyright may be reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, or by any information storage and retrieval system, without permission in writing from the copyright owner. Requests for permission to make copies of any part of the work should be mailed to Copyright Permissions, Penn Foster, 925 Oak Street, Scranton, Pennsylvania 18515. Printed in the United States of America CONTENTS INSTRUCTIONS 1 READING ASSIGNMENTS 3 LESSON 1: THE FUNDAMENTALS OF MEDICAL TERMINOLOGY 5 LESSON 2: DIAGNOSIS, INTERVENTION, AND HUMAN BODY TERMS 28 LESSON 3: MUSCULOSKELETAL, CIRCULATORY, AND RESPIRATORY SYSTEM TERMS 44 LESSON 4: DIGESTIVE, URINARY, AND REPRODUCTIVE SYSTEM TERMS 69 LESSON 5: INTEGUMENTARY, NERVOUS, AND ENDOCRINE S YSTEM TERMS 96 SELF-CHECK ANSWERS 134 © PENN FOSTER, INC. 2017 MEDICAL TERMINOLOGY PAGE III Contents INSTRUCTIONS INTRODUCTION Welcome to your course on medical terminology. You’re taking this course because you’re most likely interested in pursuing a health and science career, which entails ­proficiency­in­communicating­with­healthcare­professionals­such­as­physicians,­nurses,­ or dentists.
  • Breast Cancer Treatment What You Should Know Ta Bl E of C Onte Nts

    Breast Cancer Treatment What You Should Know Ta Bl E of C Onte Nts

    Breast Cancer Treatment What You Should Know Ta bl e of C onte nts 1 Introduction . 1 2 Taking Care of Yourself After Your Breast Cancer Diagnosis . 3 3 Working with Your Doctor or Health Care Provider . 5 4 What Are the Stages of Breast Cancer? . 7 5 Your Treatment Options . 11 6 Breast Reconstruction . 21 7 Will Insurance Pay for Surgery? . 25 8 If You Don’t Have Health Insurance . 26 9 Life After Breast Cancer Treatment . 27 10 Questions to Ask Your Health Care Team . 29 11 Breast Cancer Hotlines, Support Groups, and Other Resources . 33 12 Definitions . 35 13 Notes . 39 1 Introducti on You are not alone. There are over three million breast cancer survivors living in the United States. Great improvements have been made in breast cancer treatment over the past 20 years. People with breast cancer are living longer and healthier lives than ever before and many new breast cancer treatments have fewer side effects. The New York State Department of Health is providing this information to help you understand your treatment choices. Here are ways you can use this information: • Ask a friend or someone on your health care team to read this information along with you, or have them read it and talk about it with you when you feel ready. • Read this information in sections rather than all at once. For example, if you have just been diagnosed with breast cancer, you may only want to read Sections 1-4 for now. Sections 5-8 may be helpful while you are choosing your treatment options, and Section 9 may be helpful to read as you are finishing treatment.
  • Oncology 101 Dictionary

    Oncology 101 Dictionary

    ONCOLOGY 101 DICTIONARY ACUTE: Symptoms or signs that begin and worsen quickly; not chronic. Example: James experienced acute vomiting after receiving his cancer treatments. ADENOCARCINOMA: Cancer that begins in glandular (secretory) cells. Glandular cells are found in tissue that lines certain internal organs and makes and releases substances in the body, such as mucus, digestive juices, or other fluids. Most cancers of the breast, pancreas, lung, prostate, and colon are adenocarcinomas. Example: The vast majority of rectal cancers are adenocarcinomas. ADENOMA: A tumor that is not cancer. It starts in gland-like cells of the epithelial tissue (thin layer of tissue that covers organs, glands, and other structures within the body). Example: Liver adenomas are rare but can be a cause of abdominal pain. ADJUVANT: Additional cancer treatment given after the primary treatment to lower the risk that the cancer will come back. Adjuvant therapy may include chemotherapy, radiation therapy, hormone therapy, targeted therapy, or biological therapy. Example: The decision to use adjuvant therapy often depends on cancer staging at diagnosis and risk factors of recurrence. BENIGN: Not cancerous. Benign tumors may grow larger but do not spread to other parts of the body. Also called nonmalignant. Example: Mary was relieved when her doctor said the mole on her skin was benign and did not require any further intervention. BIOMARKER TESTING: A group of tests that may be ordered to look for genetic alterations for which there are specific therapies available. The test results may identify certain cancer cells that can be treated with targeted therapies. May also be referred to as genetic testing, molecular testing, molecular profiling, or mutation testing.
  • Inspection Examination of the Ureter and Biopsy Procedure Specific

    Inspection Examination of the Ureter and Biopsy Procedure Specific

    PATIENT INFORMATION Inspection/examination of the ureter & biopsy : procedure-specific information What is the evidence base for this information? This leaflet includes advice from consensus panels, the British Association of Urological Surgeons, the Department of Health and evidence-based sources; it is, therefore, a reflection of best practice in the UK. It is intended to supplement any advice you may already have been given by your GP or other healthcare professionals. Alternative treatments are outlined below and can be discussed in more detail with your Urologist or Specialist Nurse. What does the procedure involve? Examination of the ureter and kidney ± biopsy, with possible placement of a plastic tube or stent. This procedure usually includes cystoscopy and x-ray screening What are the alternatives to this procedure? Open surgery, other X-ray investigations or further observation Source: Urology Reference No: 5611-1 Issue date: 27.06.2014 Review date: 27.06.2016 Page 1 of 5 What should I expect before the procedure? You will usually be admitted on the same day as your surgery. You will normally receive an appointment for pre-assessment, approximately 14 days before your admission, to assess your general fitness, to screen for the carriage of MRSA and to perform some baseline investigations. After admission, you will be seen by members of the medical team which may include the Consultant, Specialist Registrar, House Officer and your named nurse. You will be asked not to eat or drink for 6 hours before surgery and, immediately before the operation, you may be given a pre-medication by the anaesthetist which will make you dry- mouthed and pleasantly sleepy.
  • Cancer Treatment and Survivorship Facts & Figures 2019-2021

    Cancer Treatment and Survivorship Facts & Figures 2019-2021

    Cancer Treatment & Survivorship Facts & Figures 2019-2021 Estimated Numbers of Cancer Survivors by State as of January 1, 2019 WA 386,540 NH MT VT 84,080 ME ND 95,540 59,970 38,430 34,360 OR MN 213,620 300,980 MA ID 434,230 77,860 SD WI NY 42,810 313,370 1,105,550 WY MI 33,310 RI 570,760 67,900 IA PA NE CT 243,410 NV 185,720 771,120 108,500 OH 132,950 NJ 543,190 UT IL IN 581,350 115,840 651,810 296,940 DE 55,460 CA CO WV 225,470 1,888,480 KS 117,070 VA MO MD 275,420 151,950 408,060 300,200 KY 254,780 DC 18,750 NC TN 470,120 AZ OK 326,530 NM 207,260 AR 392,530 111,620 SC 143,320 280,890 GA AL MS 446,900 135,260 244,320 TX 1,140,170 LA 232,100 AK 36,550 FL 1,482,090 US 16,920,370 HI 84,960 States estimates do not sum to US total due to rounding. Source: Surveillance Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute. Contents Introduction 1 Long-term Survivorship 24 Who Are Cancer Survivors? 1 Quality of Life 24 How Many People Have a History of Cancer? 2 Financial Hardship among Cancer Survivors 26 Cancer Treatment and Common Side Effects 4 Regaining and Improving Health through Healthy Behaviors 26 Cancer Survival and Access to Care 5 Concerns of Caregivers and Families 28 Selected Cancers 6 The Future of Cancer Survivorship in Breast (Female) 6 the United States 28 Cancers in Children and Adolescents 9 The American Cancer Society 30 Colon and Rectum 10 How the American Cancer Society Saves Lives 30 Leukemia and Lymphoma 12 Research 34 Lung and Bronchus 15 Advocacy 34 Melanoma of the Skin 16 Prostate 16 Sources of Statistics 36 Testis 17 References 37 Thyroid 19 Acknowledgments 45 Urinary Bladder 19 Uterine Corpus 21 Navigating the Cancer Experience: Treatment and Supportive Care 22 Making Decisions about Cancer Care 22 Cancer Rehabilitation 22 Psychosocial Care 23 Palliative Care 23 Transitioning to Long-term Survivorship 23 This publication attempts to summarize current scientific information about Global Headquarters: American Cancer Society Inc.
  • State of Science Breast Cancer Fact Sheet

    State of Science Breast Cancer Fact Sheet

    Patient Version Breast Cancer Fact Sheet About Breast Cancer Breast cancer can start in any area of the breast. In the US, breast cancer is the most common cancer (after skin cancer) and the second-leading cause of cancer death (after lung cancer) in women. Risk Factors Risk factors for breast cancer that you cannot change Lifestyle-related risk factors for breast cancer include: • Drinking alcohol Being born female • Being overweight or obese, especially after menopause This is the main risk factor for breast cancer. But men can get breast cancer, too. • Not being physically active Getting older • Getting hormone therapy after menopause with As a person gets older, their risk of breast cancer estrogen and progesterone therapy goes up. Most breast cancers are found in women • Starting menstruation early or having late menopause age 55 or older. • Never having children or having first live birth after Personal or family history age 30 A woman who has had breast cancer in the past or has a • Using certain types of birth control close blood relative who has had breast cancer (mother, • Having a history of non-cancerous breast conditions father, sister, brother, daughter) has a higher risk of getting it. Having more than one close blood relative increases the risk even more. It’s important to know that Prevention most women with breast cancer don’t have a close blood There is no sure way to prevent breast cancer, and relative with the disease. some risk factors can’t be changed, such as being born female, age, race, and personal or family history of the Inheriting gene changes disease.
  • Gastroesophageal Reflux Disease (GERD)

    Gastroesophageal Reflux Disease (GERD)

    Guidelines for Clinical Care Quality Department Ambulatory GERD Gastroesophageal Reflux Disease (GERD) Guideline Team Team Leader Patient population: Adults Joel J Heidelbaugh, MD Objective: To implement a cost-effective and evidence-based strategy for the diagnosis and Family Medicine treatment of gastroesophageal reflux disease (GERD). Team Members Key Points: R Van Harrison, PhD Diagnosis Learning Health Sciences Mark A McQuillan, MD History. If classic symptoms of heartburn and acid regurgitation dominate a patient’s history, then General Medicine they can help establish the diagnosis of GERD with sufficiently high specificity, although sensitivity Timothy T Nostrant, MD remains low compared to 24-hour pH monitoring. The presence of atypical symptoms (Table 1), Gastroenterology although common, cannot sufficiently support the clinical diagnosis of GERD [B*]. Testing. No gold standard exists for the diagnosis of GERD [A*]. Although 24-hour pH monitoring Initial Release is accepted as the standard with a sensitivity of 85% and specificity of 95%, false positives and false March 2002 negatives still exist [II B*]. Endoscopy lacks sensitivity in determining pathologic reflux but can Most Recent Major Update identify complications (eg, strictures, erosive esophagitis, Barrett’s esophagus) [I A]. Barium May 2012 radiography has limited usefulness in the diagnosis of GERD and is not recommended [III B*]. Content Reviewed Therapeutic trial. An empiric trial of anti-secretory therapy can identify patients with GERD who March 2018 lack alarm or warning symptoms (Table 2) [I A*] and may be helpful in the evaluation of those with atypical manifestations of GERD, specifically non-cardiac chest pain [II B*]. Treatment Ambulatory Clinical Lifestyle modifications.
  • Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians

    Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians

    cancers Review Diagnosis and Treatment of Bone Metastases in Breast Cancer: Radiotherapy, Local Approach and Systemic Therapy in a Guide for Clinicians Fabio Marazzi 1, Armando Orlandi 2, Stefania Manfrida 1 , Valeria Masiello 1,* , Alba Di Leone 3, Mariangela Massaccesi 1, Francesca Moschella 3, Gianluca Franceschini 3,4 , Emilio Bria 2,4, Maria Antonietta Gambacorta 1,4, Riccardo Masetti 3,4, Giampaolo Tortora 2,4 and Vincenzo Valentini 1,4 1 “A. Gemelli” IRCCS, UOC di Radioterapia Oncologica, Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (F.M.); [email protected] (S.M.); [email protected] (M.M.); [email protected] (M.A.G.); [email protected] (V.V.) 2 “A. Gemelli” IRCCS, UOC di Oncologia Medica, Dipartimento di Scienze Mediche e Chirurgiche, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (A.O.); [email protected] (E.B.); [email protected] (G.T.) 3 “A. Gemelli” IRCCS, UOC di Chirurgia Senologica, Dipartimento di Scienze della Salute della Donna e del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario, 00168 Roma, Italy; [email protected] (A.D.L.); [email protected] (F.M.); [email protected] (G.F.); [email protected] (R.M.) 4 Istituto di Radiologia, Università Cattolica del Sacro Cuore, 00168 Roma, Italy * Correspondence: [email protected] Received: 1 May 2020; Accepted: 20 August 2020; Published: 24 August 2020 Abstract: The standard care for metastatic breast cancer (MBC) is systemic therapies with imbrication of focal treatment for symptoms.
  • Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights

    Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights

    biomolecules Review Insulin/IGF Axis in Breast Cancer: Clinical Evidence and Translational Insights Federica Biello 1,* , Francesca Platini 2, Francesca D’Avanzo 2, Carlo Cattrini 2 , Alessia Mennitto 2, Silvia Genestroni 2, Veronica Martini 2,3, Paolo Marzullo 1,4 , Gianluca Aimaretti 1 and Alessandra Gennari 1 1 Department of Translational Medicine, University of Eastern Piedmont, Via Solaroli 17, 28100 Novara, Italy; [email protected] (P.M.); [email protected] (G.A.); [email protected] (A.G.) 2 Division of Oncology, University Hospital “Maggiore della Carità”, 28100 Novara, Italy; [email protected] (F.P.); [email protected] (F.D.); [email protected] (C.C.); [email protected] (A.M.); [email protected] (S.G.); [email protected] (V.M.) 3 Lab of Immuno-Oncology, CAAD, Center of Autoimmune and Allergic Disease, University of Eastern Piedmont, 28100 Novara, Italy 4 Division of General Medicine, IRCCS Istituto Auxologico Italiano, Ospedale S. Giuseppe, 28921 Piancavallo-Verbania, Italy * Correspondence: [email protected] Abstract: Background: Breast cancer (BC) is the most common neoplasm in women. Many clinical and preclinical studies investigated the possible relationship between host metabolism and BC. Significant differences among BC subtypes have been reported for glucose metabolism. Insulin can promote tumorigenesis through a direct effect on epithelial tissues